{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T15:20:04Z","timestamp":1758381604777,"version":"3.44.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jpharmsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.xphs.2019.09.008","type":"journal-article","created":{"date-parts":[[2019,9,12]],"date-time":"2019-09-12T01:58:50Z","timestamp":1568253530000},"page":"3785-3791","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Quality by Design-Driven Process Development of Severe Fever With Thrombocytopenia Syndrome Vaccine"],"prefix":"10.1016","volume":"108","author":[{"given":"Xinran","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yankun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rongbin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guoqiang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiuxia","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunli","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Deng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhonghu","family":"Bai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.xphs.2019.09.008_bib1","series-title":"Medical Microbiology","article-title":"Bunyaviruses","author":"Shope","year":"1996"},{"issue":"Pt 3","key":"10.1016\/j.xphs.2019.09.008_bib2","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1099\/0022-1317-71-3-501","article-title":"Molecular biology of the Bunyaviridae","volume":"71","author":"Elliott","year":"1990","journal-title":"J\u00a0Gen Virol"},{"issue":"16","key":"10.1016\/j.xphs.2019.09.008_bib3","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1056\/NEJMoa1010095","article-title":"Fever with thrombocytopenia associated with a novel bunyavirus in China","volume":"364","author":"Yu","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.xphs.2019.09.008_bib4","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/978-1-4614-0980-9_11","article-title":"Bunyavirus: structure and replication","volume":"726","author":"Guu","year":"2012","journal-title":"Adv Exp Med Biol"},{"issue":"7","key":"10.1016\/j.xphs.2019.09.008_bib5","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1073\/pnas.0708738105","article-title":"Insights into bunyavirus architecture from electron cryotomography of Uukuniemi virus","volume":"105","author":"Overby","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"10.1016\/j.xphs.2019.09.008_bib6","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1586\/erv.09.19","article-title":"Vero cell platform in vaccine production: moving towards cell culture-based viral vaccines","volume":"8","author":"Barrett","year":"2009","journal-title":"Expert Rev Vaccin"},{"issue":"5","key":"10.1016\/j.xphs.2019.09.008_bib7","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1007\/s00253-015-7267-9","article-title":"Bioreactors for high cell density and continuous multi-stage cultivations: options for process intensification in cell culture-based viral vaccine production","volume":"100","author":"Tapia","year":"2016","journal-title":"Appl Microbiol Biotechnol"},{"issue":"5","key":"10.1016\/j.xphs.2019.09.008_bib8","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1002\/biot.201400388","article-title":"Designing cell lines for viral vaccine production: where do we stand?","volume":"10","author":"Genzel","year":"2015","journal-title":"Biotechnol J"},{"issue":"109","key":"10.1016\/j.xphs.2019.09.008_bib9","first-page":"27325","article-title":"International Conference on Harmonisation; guidance on Q8(R1) pharmaceutical development; addition of annex; availability. Notice","volume":"74","year":"2009","journal-title":"Fed Regist"},{"issue":"106","key":"10.1016\/j.xphs.2019.09.008_bib10","first-page":"32105","article-title":"International Conference on Harmonisation; guidance on Q9 quality risk management; availability. Notice","volume":"71","year":"2006","journal-title":"Fed Regist"},{"issue":"66","key":"10.1016\/j.xphs.2019.09.008_bib11","first-page":"15990","article-title":"International Conference on Harmonisation; guidance on Q10 pharmaceutical quality system; availability. Notice","volume":"74","year":"2009","journal-title":"Fed Regist"},{"issue":"224","key":"10.1016\/j.xphs.2019.09.008_bib12","first-page":"69634","article-title":"International Conference on Harmonisation; guidance on Q11 development and manufacture of drug substances; availability. Notice","volume":"77","year":"2012","journal-title":"Fed Regist"},{"issue":"24","key":"10.1016\/j.xphs.2019.09.008_bib13","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1016\/j.vaccine.2014.02.028","article-title":"Implementation of QbD for the development of a vaccine candidate","volume":"32","author":"Haas","year":"2014","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.xphs.2019.09.008_bib14","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1002\/btpr.2402","article-title":"Exploring the linkage between cell culture process parameters and downstream processing utilizing a plackett-burman design for a model monoclonal antibody","volume":"33","author":"Agarabi","year":"2017","journal-title":"Biotechnol Prog"},{"issue":"4","key":"10.1016\/j.xphs.2019.09.008_bib15","first-page":"773","article-title":"The measurement of proliferation in tissue cultures by enumeration of cell nuclei","volume":"11","author":"Sanford","year":"1951","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"1-2","key":"10.1016\/j.xphs.2019.09.008_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0168-1702(01)00273-8","article-title":"Construction, characterization and immunogenicity of recombinant yellow fever 17D-dengue type 2 viruses","volume":"79","author":"Caufour","year":"2001","journal-title":"Virus Res"},{"issue":"1","key":"10.1016\/j.xphs.2019.09.008_bib17","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1021\/bp060359c","article-title":"Using statistical analysis for setting process validation acceptance criteria for biotech products","volume":"23","author":"Wang","year":"2007","journal-title":"Biotechnol Prog"},{"issue":"2","key":"10.1016\/j.xphs.2019.09.008_bib18","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1006\/viro.1997.8538","article-title":"Amplification of recombinant adenoviral transgene products occurs by inhibition of histone deacetylase","volume":"231","author":"Dion","year":"1997","journal-title":"Virology"},{"issue":"2","key":"10.1016\/j.xphs.2019.09.008_bib19","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1006\/viro.1994.1390","article-title":"NF-kappa B-dependent and -independent pathways of HIV activation in a chronically infected T cell line","volume":"202","author":"Antoni","year":"1994","journal-title":"Virology"},{"issue":"2","key":"10.1016\/j.xphs.2019.09.008_bib20","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1006\/viro.1993.1505","article-title":"Sodium butyrate treatment of cells latently infected with HIV-1 results in the expression of unspliced viral RNA","volume":"196","author":"Laughlin","year":"1993","journal-title":"Virology"},{"issue":"2","key":"10.1016\/j.xphs.2019.09.008_bib21","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/0042-6822(86)90218-7","article-title":"Butyrate-induced reversal of herpes simplex virus restriction in neuroblastoma cells","volume":"155","author":"Ash","year":"1986","journal-title":"Virology"},{"issue":"3","key":"10.1016\/j.xphs.2019.09.008_bib22","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1023\/A:1020555310558","article-title":"Development and improvement of a serum-free suspension process for the production of recombinant adenoviral vectors using HEK293 cells","volume":"37","author":"Tsao","year":"2001","journal-title":"Cytotechnology"},{"issue":"3","key":"10.1016\/j.xphs.2019.09.008_bib23","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1007\/s12257-009-3032-1","article-title":"Effects of calcium ion on adenovirus production with high densities of HEK293 cells","volume":"15","author":"Liu","year":"2010","journal-title":"Biotechnol Bioproc Eng"},{"year":"2012","series-title":"A-VAX: Applying Quality by Design to Vaccines","key":"10.1016\/j.xphs.2019.09.008_bib24"},{"issue":"6","key":"10.1016\/j.xphs.2019.09.008_bib25","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1002\/btpr.672","article-title":"Application of quality by design principles to the development and technology transfer of a major process improvement for the manufacture of a recombinant protein","volume":"27","author":"Looby","year":"2011","journal-title":"Biotechnol Prog"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354919305799?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354919305799?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T09:29:27Z","timestamp":1758360567000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354919305799"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":25,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["S0022354919305799"],"URL":"https:\/\/doi.org\/10.1016\/j.xphs.2019.09.008","relation":{},"ISSN":["0022-3549"],"issn-type":[{"type":"print","value":"0022-3549"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Quality by Design-Driven Process Development of Severe Fever With Thrombocytopenia Syndrome Vaccine","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xphs.2019.09.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 American Pharmacists Association\u00ae. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}